Literature DB >> 21533703

Behavioral factors in the placebo response.

R E Weeks1, E Newman.   

Abstract

Given its presence in almost every clinical trial, the placebo is the most frequently studied substance in clinical research. Demonstration of treatment efficacy demands that the target (active) agent must be shown to be statistically significantly superior to an inert substance (placebo) not believed to be a specific therapy for the target condition. In clinical practice, enhancing the non-specific factors that contribute to an enhanced treatment outcome is desirable to maximize the likelihood of therapeutic benefit. Variables affecting the impact of placebo on clinical research and practice remain poorly understood, however, as they have not been systematically studied. The present article will discuss behavioral factors that have been found to be relevant in placebo mechanisms.

Mesh:

Year:  2011        PMID: 21533703     DOI: 10.1007/s10072-011-0555-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  33 in total

1.  Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials.

Authors:  H C Diener; A J Dowson; M Ferrari; G Nappi; P Tfelt-Hansen
Journal:  Cephalalgia       Date:  1999-10       Impact factor: 6.292

2.  Response variability to analgesics: a role for non-specific activation of endogenous opioids.

Authors:  Martina Amanzio; Antonella Pollo; Giuliano Maggi; Fabrizio Benedetti
Journal:  Pain       Date:  2001-02-15       Impact factor: 6.961

3.  Response expectancies in placebo analgesia and their clinical relevance.

Authors:  Antonella Pollo; Martina Amanzio; Anna Arslanian; Caterina Casadio; Giuliano Maggi; Fabrizio Benedetti
Journal:  Pain       Date:  2001-07       Impact factor: 6.961

4.  The powerful placebo.

Authors:  H K BEECHER
Journal:  J Am Med Assoc       Date:  1955-12-24

Review 5.  A comprehensive review of the placebo effect: recent advances and current thought.

Authors:  Donald D Price; Damien G Finniss; Fabrizio Benedetti
Journal:  Annu Rev Psychol       Date:  2008       Impact factor: 24.137

6.  Commercial features of placebo and therapeutic efficacy.

Authors:  Rebecca L Waber; Baba Shiv; Ziv Carmon; Dan Ariely
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

7.  Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.

Authors:  S D Silberstein; H Göbel; R Jensen; A H Elkind; R Degryse; J M C M Walcott; C Turkel
Journal:  Cephalalgia       Date:  2006-07       Impact factor: 6.292

8.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

Review 9.  Placebo--efficacy and adverse effects in controlled clinical trials.

Authors:  T R Weihrauch; T C Gauler
Journal:  Arzneimittelforschung       Date:  1999-05

Review 10.  Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.

Authors:  Jeffrey A Bridge; Boris Birmaher; Satish Iyengar; Rémy P Barbe; David A Brent
Journal:  Am J Psychiatry       Date:  2008-12-01       Impact factor: 18.112

View more
  1 in total

1.  Predictors of Short-Term Prognosis While in Pediatric Headache Care: An Observational Study.

Authors:  Serena L Orr; Abigail Turner; Marielle A Kabbouche; Paul S Horn; Hope L O'Brien; Joanne Kacperski; Susan LeCates; Shannon White; Jessica Weberding; Mimi N Miller; Scott W Powers; Andrew D Hershey
Journal:  Headache       Date:  2019-01-23       Impact factor: 5.887

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.